@article{d205cef9b9e249a0a28416de2af8529f,
title = "Reply: Endovascular-First Treatment of Peripheral Arterial Disease Remains Controversial",
author = "Olin, \{Jeffrey W.\} and White, \{Christopher J.\} and Armstrong, \{Ehrin J.\} and Daniella Kadian-Dodov and Hiatt, \{William R.\}",
note = "Funding Information: Please note: Dr. Olin serves on the steering committee and scientific advisory board for Merck for the TRAP2 trial; serves on the international steering committee for the EUCLID TRIAL; and is a site investigator for AstraZeneca. Dr. White serves on the research advisory board for Lutonix and Surmodics. Dr. Armstrong is a consultant/advisory board member for Abbott Vascular, Medtronic, Merck, Pfizer, and Spectranetics. Dr. Hiatt has received grant support for clinical trials research from AstraZeneca, Bayer, Janssen, GSK, ReNeuron, and the National Institutes of Health. Dr. Kadian-Dodov has reported that she has no relationships relevant to the contents of this paper to disclose. ",
year = "2016",
month = sep,
day = "27",
doi = "10.1016/j.jacc.2016.07.725",
language = "English",
volume = "68",
pages = "1493",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier Inc.",
number = "13",
}